KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Operating Leases (2019 - 2025)

Twist Bioscience (TWST) has disclosed Operating Leases for 4 consecutive years, with $81.3 million as the latest value for Q3 2022.

  • On a quarterly basis, Operating Leases rose 52.89% to $81.3 million in Q3 2022 year-over-year; TTM through Sep 2022 was $81.3 million, a 52.89% increase, with the full-year FY2022 number at $81.3 million, up 52.89% from a year prior.
  • Operating Leases was $81.3 million for Q3 2022 at Twist Bioscience, up from $64.2 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $81.3 million in Q3 2022 to a low of $22.2 million in Q1 2021.
  • A 4-year average of $45.9 million and a median of $43.7 million in 2020 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: plummeted 34.99% in 2021, then soared 258.13% in 2022.
  • Twist Bioscience's Operating Leases stood at $27.5 million in 2019, then fell by 14.01% to $23.7 million in 2020, then skyrocketed by 154.57% to $60.3 million in 2021, then soared by 34.81% to $81.3 million in 2022.
  • Per Business Quant, the three most recent readings for TWST's Operating Leases are $81.3 million (Q3 2022), $64.2 million (Q2 2022), and $79.7 million (Q1 2022).